Icosapent ethyl

A prescription medicine, sold as Vascepa, that is an ethyl ester of eicosapentaenoic acid (EPA), an omega-3 fatty acid. The US label lists it for lowering very high triglycerides in adults, and, added to a statin, for lowering the risk of heart attack, stroke and some other events in adults with raised triglycerides and either established cardiovascular disease or diabetes plus other risk factors. The label warns of a higher risk of atrial fibrillation or atrial flutter needing hospital care, and of bleeding.

Also called Vascepa

  • Drug
  • In this atlas

Overview

Technical summary

RxNorm ingredient 1304974. NDA202057, with an original submission dated 2012-07-26 in the openFDA record. The evidence recorded here is the Amarin label and the FDA record only; this record reads no outcome trial.

Trials at a glance

The figures count the 4 registry trials in this atlas that name this drug or a product that contains it. Trials that use another name for it are not counted.

Trials
4
Phase 3 or 4
2
Recruiting
0
Regulatory decisions
0
Trials by phase (rows) and registry status (columns)
PhaseNot yet recruitingActive, not recruitingCompletedTerminatedAll statuses
Phase 201102
Phase 410012
All phases11114

Conditions these trials study

Sponsors with the most trials

The lead sponsor of each trial, as the registry names it.

About this drug

Level
Substance
Mechanism
The label says studies suggest that EPA reduces liver production or release of very low-density lipoprotein triglycerides and enhances triglyceride clearance from circulating VLDL particles. It says the mechanisms behind fewer cardiovascular events are not completely understood.

Claims and evidence

Context Adults with raised triglycerides, as the US Vascepa label describes them

Recipient
Adult
Population
Adult patients named in the indications of the US label for Vascepa: adults with elevated triglycerides and established cardiovascular disease or diabetes plus other risk factors, and adults with severe hypertriglyceridemia.
Care setting
Prescription medicine; the label adds the medicine to statin treatment or to diet, as stated in the indications
Geography
United States (FDA label)
Life stage
Adults; the label states adult patients
Follow-up
Not applicable (label text and a regulatory record)
Eligibility: inclusion criteria not stated; exclusion criteria not stated
Included
None stated
Excluded
None stated
  • Regulatory Evidence stage not applicable Certainty not assessed

    The openFDA Drugs@FDA record for NDA202057 lists Vascepa, from AMARIN PHARMS, with an original submission (ORIG 1) in status AP (approved) dated 26 July 2012.

    Applies to Adult Adults with raised triglycerides, as the US Vascepa label describes them

    Certainty method
    Not assessed
    Limitations
    An openFDA record, which openFDA says is unvalidated. It gives dates as compact numbers and does not state the indication approved in 2012; the label indications above are the current ones.
    Last checked
    2026-10-30
    Next evidence check due
    Not scheduled
    Sources and citations (2)
    1. Supports FDA New Drug Application NDA202057: Vascepa (openFDA drugsfda record)

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drugsfda record for application NDA202057 returned on 2026-10-30. It writes dates as compact numbers (YYYYMMDD). · NDA: NDA202057

      Locator
      results[0].submissions[16]
      How it applies
      Original submission in the FDA record.
      Retrieved
      Source effective date
      Not reported
      Source state
      Current
      Version fingerprint
      41292867e3d790ed006a0ecfafa198151a08bf8d01aee67bc6385f643593a81f
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication unless noted, as the openFDA terms page states (fetched 2026-10-30, sha256 b11f712bfb11d03319675fc04e6948133a83c57aa2913b7f18d3677d0209f723, hash only). The raw record is committed in the atlas repository.
    2. Supports FDA New Drug Application NDA202057: Vascepa (openFDA drugsfda record)

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drugsfda record for application NDA202057 returned on 2026-10-30. It writes dates as compact numbers (YYYYMMDD). · NDA: NDA202057

      Locator
      results[0].sponsor_name
      How it applies
      Applicant name in the FDA record.
      Retrieved
      Source effective date
      Not reported
      Source state
      Current
      Version fingerprint
      41292867e3d790ed006a0ecfafa198151a08bf8d01aee67bc6385f643593a81f
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication unless noted, as the openFDA terms page states (fetched 2026-10-30, sha256 b11f712bfb11d03319675fc04e6948133a83c57aa2913b7f18d3677d0209f723, hash only). The raw record is committed in the atlas repository.
  • Description Evidence stage not applicable Certainty not assessed

    The US Vascepa label says Vascepa (icosapent ethyl) is indicated, as an add-on to statin treatment at the highest dose the patient can tolerate, to reduce the risk of myocardial infarction, stroke, coronary revascularization and unstable angina requiring hospitalization in adult patients with elevated triglyceride levels (150 mg/dL or higher) and established cardiovascular disease or diabetes mellitus and 2 or more additional risk factors for cardiovascular disease. It is also indicated, as an adjunct to diet, to reduce triglyceride levels in adult patients with severe (500 mg/dL or higher) hypertriglyceridemia. The label says the effect on the risk of pancreatitis in patients with severe hypertriglyceridemia has not been determined.

    Applies to Adult Adults with raised triglycerides, as the US Vascepa label describes them

    Certainty method
    Not assessed
    Limitations
    These are indications as the label states them, in the label version dated 2026-03-23. They say what FDA has approved the medicine for, not how well it works for any person. The trial evidence behind the cardiovascular indication is not read in this atlas yet.
    Last checked
    2026-10-30
    Next evidence check due
    Not scheduled
    Sources and citations (1)
    1. Supports Vascepa drug label (openFDA record, set id 9c1a2828-1583-4414-ab22-a60480e8e508)

      Label · U.S. Food and Drug Administration (openFDA drug label endpoint) · Edition openFDA drug label record for the Amarin Pharma Inc. label of Vascepa, label effective 20260323, fetched 2026-10-30. · SPL set id: 9c1a2828-1583-4414-ab22-a60480e8e508

      Locator
      results[0].indications_and_usage[0]
      How it applies
      Label indications and limitations of use.
      Retrieved
      Source effective date
      2026-03-23
      Source state
      Current
      Version fingerprint
      12fe4482da2226bca5532a6f564670e78bc340e93b515177b8741bd0a6f5aebd
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication unless noted (https://open.fda.gov/terms/, fetched 2026-10-30, sha256 b11f712bfb11d03319675fc04e6948133a83c57aa2913b7f18d3677d0209f723, hash only). The label text is the manufacturer's labeling as FDA publishes it; check the openFDA documentation for a not-in-the-public-domain warning before quoting beyond short passages. The raw file is committed in the atlas repository.
  • Safety Evidence stage not applicable Certainty not assessed

    The US Vascepa label says Vascepa is associated with an increased risk of atrial fibrillation or atrial flutter requiring hospitalization, and with an increased risk of bleeding.

    Applies to Adult Adults with raised triglycerides, as the US Vascepa label describes them

    Certainty method
    Not assessed
    Limitations
    Warnings as the label states them, in the label version dated 2026-03-23. The label gives event counts from one trial; this atlas does not repeat them and has not read the trial.
    Last checked
    2026-10-30
    Next evidence check due
    Not scheduled
    Sources and citations (1)
    1. Supports Vascepa drug label (openFDA record, set id 9c1a2828-1583-4414-ab22-a60480e8e508)

      Label · U.S. Food and Drug Administration (openFDA drug label endpoint) · Edition openFDA drug label record for the Amarin Pharma Inc. label of Vascepa, label effective 20260323, fetched 2026-10-30. · SPL set id: 9c1a2828-1583-4414-ab22-a60480e8e508

      Locator
      results[0].warnings_and_cautions[0]
      How it applies
      Label warnings and precautions, sections 5.1 and 5.3.
      Retrieved
      Source effective date
      2026-03-23
      Source state
      Current
      Version fingerprint
      12fe4482da2226bca5532a6f564670e78bc340e93b515177b8741bd0a6f5aebd
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication unless noted (https://open.fda.gov/terms/, fetched 2026-10-30, sha256 b11f712bfb11d03319675fc04e6948133a83c57aa2913b7f18d3677d0209f723, hash only). The label text is the manufacturer's labeling as FDA publishes it; check the openFDA documentation for a not-in-the-public-domain warning before quoting beyond short passages. The raw file is committed in the atlas repository.

FDA label

Assembled by a program from the openFDA drug label dataset, retrieved 8 November 2026, for the products that contain this drug: the label of the application holder or its company group, never a repackager's. Data provided by the U.S. Food and Drug Administration (open.fda.gov). The label is a manufacturer's submission that FDA has not verified, and the label on the product may differ. 1 label below.

VASCEPA

Application
NDA202057
Labeler
Amarin Pharma Inc.
Label version
Version 21, effective
Label set id
9c1a2828-1583-4414-ab22-a60480e8e508
Boxed warning
No boxed warning
Sections the label has
Indications and usage Contraindications Warnings and cautions Adverse reactions Drug interactions Use in specific populations Pregnancy Pediatric use Geriatric use Clinical pharmacology Clinical studies

FDA decisions timeline

The regulatory decisions of the FDA that this atlas holds for this drug and the products that contain it, oldest first. Each links to its full record.

  1. Approval NDA202057 VASCEPA
  2. Supplemental approval NDA202057 VASCEPA

Clinical links

Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.

Registry records

Assembled by a program from ClinicalTrials.gov and openFDA. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.

Registry products 1

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 1 efficacy supplement approval on record.

    ProductNDA202057

Registry trials 4

Record details

Record id
cardio:icosapent-ethyl
Content hash
319e7ae642de075482d2d07a486fe7995f79a4494b07e88818f113640e3fa83c